Blood Clotting Disorders

Beriate P

Beriate P contains human coagulation factor VIII.
It is used to treat and prevent bleeding in patients with Hemophilia A (congenital deficiency of factor VIII).
The drug may be used to treat patients with an acquired factor VIII deficiency.
The drug does not contain von Willebrand factor in an effective dose and therefore is not indicated for treatment of the von Willebrand disease.

Haemate P

Haemate P contains active human ingredient von Willebrand factor and the human coagulation factor VIII. 

Therapeutic indications:
Von Willebrand Disease (VWD)
Prophylaxis and treatment of hemorrhage or bleeding in a surgery when individual Desmopressin (DDAVP) treatment is ineffective and contraindicated.

Hemophilia A (congenital deficiency of factor VIII)
Prophylaxis and treatment of bleeding. The drug is used to treat acquired factor VIII deficiency and patients with antibodies to factor VIII.

Berinin P

The drug contains human coagulation factor IX. It is used to treat and prevent bleeding in patients with hemophilia B (congenital factor IX deficiency) and with the acquired factor IX deficiency.

Beriplast P

Beriplast P is a biological tissue adhesive on the basis of human fibrinogen. It can be used locally as a supportive treatment where standard surgical disciplines are insufficient for improvement of hemostasis (including endoscopic treatment of bleeding gastroduodenal ulcers), as a tissue adhesive to promote bonding/gluing of tissue or for surgical sutures fusing.

Immunology

Privigen

Privigen is a normal 10% liquid of human immunoglobulin (IVIG), 100 mg/ml of infusion intravenous liquid.
It is used in the following therapeutic indications:

Substitute therapy

for primary immunodeficiency (PID) such as:

  • Congenital agammaglobulinemia a hypogammaglobulinemia
  • Common variable immunodeficiency (CVID)
  • Severe combined immunodeficiency
  • Wiskott-Aldrich syndrome
  • Myeloma or chronic lymphocytic leukemia with a severe secondary hypogammaglobulinemia and repeated infections
  • Congenital AIDS with recurring infections in children

Immunomodulation

  • Chronic immune thrombocytopenic purpura in children or adults with severe bleeding potential or before a surgical procedure for platelet count modification
  • Guillain-Barré Syndrome
  • Kawasaki Disease

Allogenic bone marrow transplant

 
Hizentra

The medication contains human immunoglobulin; 200 mg/ml injection solution designed for a subcutaneous injection.  20% immunoglobulin therapy shortens infusion times.

Therapeutic Indications:
A substitute treatment for children and adults living with the primary immunodeficiency disease, such as:

  • Congenital agammaglobulinemia and hypogammaglobulinemia
  • Common variable immunodeficiency
  • Severe combined immunodeficiency
  • IgG subclass deficiency with recurring infections

A substitute treatment for patients with myeloma or chronic lymphocytic leukemia with a severe secondary hypogammaglobulinemia and recurring infections.  

The medication is designed for a subcutaneous use only. Hizentra can be administered into the stomach, thighs, upper arm, or the hip. If the dose is more than 25 ml, it is recommended to administer in separate doses and different infusion sites.  

Infusion pumps are suitable for a subcutaneous administration of immunoglobulin, as well as ‘Rapid push’ form – an easy subcutaneous application for a home treatment where the infusion pump is not necessary.

Rhophylac

The drug contains human anti – D immunoglobulin (300 mcgs in 2 ml). It is used in the following therapeutic indications:

Prevention of Rh(D) immunization in Rh(D) negative women

  • Antepartum prophylaxis
  • Planned antepartum prophylaxis
  • Antepartum prophylaxis with the following complications in pregnancy:

abortion / threatened abortion, ectopic pregnancy or hydatidiform mole, intrauterine fetal death (IUFD), transplacental hemorrhage (TPH) resulting from ante-partum hemorrhage (APH), amniocentesis, chorionic biopsy, obstetric interventions such as fetal positioning, invasive procedures, cordocentesis, blunt abdominal trauma or fetal surgery.

  • Postpartum prophylaxis
  • Birth of a Rh(D) positive (D, weak D, partial D) newborn                   

Incompatible transfusions in Rh(D) negative individuals transfused with blood components containing Rh(D) positive red blood cells or other products with erythrocytes (platelet concentrate)

Berinert P

The drug contains the protein C1 esterase inhibitor. It is used in treatment of acute abdominal or facial attacks of hereditary type I and II angioedema (HAE) in adult and adolescent patients.